DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2023 Conference Call.
Source: insidermonkey.com
Scott Kasner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Scott Kasner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Scott Kasner Today - Breaking & Trending Today
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy ...
Source: marketscreener.com
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
Conference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Team Expanded with Addition... | March 14, 2022
Source: marketscreener.com
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
PFO Closure for Stroke Is Safe, Effective at 5 Years: REDUCE
March 15, 2021 Five-year results from the randomized REDUCE trial show a continued benefit of patent foramen ovale (PFO) closure compared with antiplatelet therapy alone for the prevention of cryptogenic stroke. “Most importantly, this supports the idea that PFO closure in appropriately selected patients has a durable effect with longer-term safety,” lead author Scott Kasner, MD (University of Pennsylvania, Philadelphia), told TCTMD. “Of the prior studies, only one had long-term data. That was the RESPECT PFO trial. The others were all of similar length to the original Gore results [fro...
Source: tctmd.com